{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:34:32Z","timestamp":1792114472803,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,9,4]],"date-time":"2014-09-04T00:00:00Z","timestamp":1409788800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s00198-014-2872-5","type":"journal-article","created":{"date-parts":[[2014,9,3]],"date-time":"2014-09-03T06:23:11Z","timestamp":1409725391000},"page":"499-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Incidence of ocular side effects with intravenous zoledronate: secondary analysis of a randomized controlled trial"],"prefix":"10.1007","volume":"26","author":[{"given":"D. V.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Nisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Al-Abuwsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. R.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. N. J.","family":"McGhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,4]]},"reference":[{"key":"2872_CR1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u201322","journal-title":"N Engl J Med"},{"key":"2872_CR2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1359\/jbmr.061001","volume":"22","author":"D Hosking","year":"2007","unstructured":"Hosking D, Lyles K, Brown JP et al (2007) Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. J Bone Miner Res 22:142\u20138","journal-title":"J Bone Miner Res"},{"key":"2872_CR3","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357:1799\u2013809","journal-title":"N Engl J Med"},{"key":"2872_CR4","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","volume":"95","author":"IR Reid","year":"2010","unstructured":"Reid IR, Gamble GD, Mesenbrink P et al (2010) Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab 95:4380\u20137","journal-title":"J Clin Endocrinol Metab"},{"key":"2872_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/8756-3282(95)00448-3","volume":"18","author":"A Sauty","year":"1996","unstructured":"Sauty A, Pecherstorfer M, Zimmer-Roth I et al (1996) Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone 18:133\u20139","journal-title":"Bone"},{"key":"2872_CR6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199903043400914","volume":"340","author":"V Kunzmann","year":"1999","unstructured":"Kunzmann V, Bauer E, Wilhelm M (1999) Gamma\/delta T-cell stimulation by pamidronate. N Engl J Med 340:737\u20138","journal-title":"N Engl J Med"},{"key":"2872_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/sj.eye.6701461","volume":"19","author":"JM Durnian","year":"2005","unstructured":"Durnian JM, Olujohungbe A, Kyle G (2005) Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye 19:221\u20132","journal-title":"Eye"},{"key":"2872_CR8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clon.2006.04.013","volume":"18","author":"TCS Woo","year":"2006","unstructured":"Woo TCS, Joseph DJ, Wilkinson R (2006) Serious ocular complications of zoledronate. Clin Oncol R Coll Radiol 18:545\u20136","journal-title":"Clin Oncol R Coll Radiol"},{"key":"2872_CR9","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.4158\/EP11081.CR","volume":"17","author":"H Kaur","year":"2011","unstructured":"Kaur H, Uy C, Kelly J et al (2011) Orbital inflammatory disease in a patient treated with zoledronate. Endocr Pract 17:e101\u20133","journal-title":"Endocr Pract"},{"key":"2872_CR10","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.ophtha.2012.10.028","volume":"120","author":"DV Patel","year":"2013","unstructured":"Patel DV, Horne A, House M et al (2013) The incidence of acute anterior uveitis after intravenous zoledronate. Ophthalmology 120:773\u20136","journal-title":"Ophthalmology"},{"issue":"3","key":"2872_CR11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"DA Jabs","year":"2005","unstructured":"Jabs DA, Nussenblatt RB, Rosenbaum JT et al (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 140(3):509\u201316","journal-title":"Am J Ophthalmol"},{"key":"2872_CR12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2165\/00002018-200629020-00005","volume":"29","author":"B Aurich-Barrera","year":"2006","unstructured":"Aurich-Barrera B, Wilton L, Harris S et al (2006) Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England. Drug Saf 29:151\u201360","journal-title":"Drug Saf"},{"key":"2872_CR13","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/IAE.0b013e31816576ef","volume":"28","author":"DD French","year":"2008","unstructured":"French DD, Margo CE (2008) Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort. Retina 28:889\u201393","journal-title":"Retina"},{"key":"2872_CR14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1136\/ard.62.4.378","volume":"62","author":"P Fietta","year":"2003","unstructured":"Fietta P, Manganelli P, Lodigiani L (2003) Clodronate induced uveitis. Ann Rheum Dis 62:378","journal-title":"Ann Rheum Dis"},{"key":"2872_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2407-5-156","volume":"5","author":"NS Saghir El","year":"2005","unstructured":"El Saghir NS, Otrock ZK, Bleik JH (2005) Unilateral anterior uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer 5:156","journal-title":"BMC Cancer"},{"key":"2872_CR16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/01.ico.0000225713.00630.e5","volume":"25","author":"JC Richards","year":"2006","unstructured":"Richards JC, Wiffen SJ (2006) Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy. Cornea 25:1100\u20131","journal-title":"Cornea"},{"key":"2872_CR17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","volume":"118","author":"V Macarol","year":"1994","unstructured":"Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118:220\u20134","journal-title":"Am J Ophthalmol"},{"key":"2872_CR18","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM200303203481225","volume":"348","author":"FW Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348:1187\u20138","journal-title":"N Engl J Med"},{"key":"2872_CR19","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1136\/bjo.2008.146753","volume":"94","author":"D Wakefield","year":"2010","unstructured":"Wakefield D, Gray P, Chang J et al (2010) The role of PAMPs and DAMPs in the pathogenesis of acute and recurrent anterior uveitis. Br J Ophthalmol 94:271\u20134","journal-title":"Br J Ophthalmol"},{"key":"2872_CR20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","volume":"144","author":"AJ Roelofs","year":"2009","unstructured":"Roelofs AJ, Jauhiainen M, Monkkonen H et al (2009) Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP. Br J Haematol 144:245\u201350","journal-title":"Br J Haematol"},{"key":"2872_CR21","unstructured":"Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version. www.OpenEpi.com , updated 2013\/04\/06. Accessed 13 Jan 2014"},{"key":"2872_CR22","unstructured":"Graphpad Quickcalcs http:\/\/graphpad.com\/quickcalcs\/NNT1.cfm . Accessed 14 Jan 2014"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2872-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-014-2872-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-014-2872-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T11:15:16Z","timestamp":1558610116000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-014-2872-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["2872"],"URL":"https:\/\/doi.org\/10.1007\/s00198-014-2872-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,4]]}}}